Lifecore Biomedical Reiterates FY25 Outlook: Sees Revenues Of $126.5M-$130M (Estimate: $127.56M) And Adjusted EBITDA Of $19M-$21M
Portfolio Pulse from Nabaparna Bhattacharya
Lifecore Biomedical has reiterated its financial outlook for FY25, projecting revenues between $126.5 million and $130 million, and adjusted EBITDA between $19 million and $21 million. These projections align closely with market estimates.
October 04, 2024 | 11:41 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lifecore Biomedical has reiterated its FY25 financial outlook, with revenue projections of $126.5M-$130M and adjusted EBITDA of $19M-$21M, aligning with market estimates.
The reaffirmation of Lifecore's FY25 outlook suggests stability and predictability in its financial performance, which aligns with market expectations. This is likely to maintain investor confidence but may not significantly impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100